ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) is a biopharmaceutical company focused on commercializing and developing neffy, a needle-free nasal spray delivering epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Its product contains epinephrine and the absorption enhancer Intravail;… From the company’s description.
Over the twelve months to Sep 30, 2026, ARS Pharmaceuticals, Inc. reported revenue of $122.14M, down 14.5% from a year earlier, and a net loss of $199.87M. Its operating margin was −161.5%, and operations used $183.07M in cash. In fiscal 2025, it reported revenue of $84.28M, down 5.5% from fiscal 2024, and a net loss of $171.30M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ARS Pharmaceuticals, Inc. does
In the company’s own words
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) is a biopharmaceutical company focused on commercializing and developing neffy, a needle-free nasal spray delivering epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Its product contains epinephrine and the absorption enhancer Intravail; the 2 mg dose is approved for adults and children weighing at least 30 kg, and the 1 mg dose for patients aged four and older weighing 15 kg to less than 30 kg in certain markets. The product is marketed as EURneffy in the European Union and United Kingdom and as 优敏速 in China. ARS sells neffy directly in the United States and works with regional partners, including ALK, Alfresa, Pediatrix and Seqirus, to develop and commercialize it internationally. The company is also studying neffy for chronic urticaria, including in a Phase 2b trial initiated in 2025. In February 2026, its U.S. commercial effort included a 106-person direct sales force and approximately 70 sales representatives through a co-promotion arrangement with ALK U.S.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1671858
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ARS Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in ARS Pharmaceuticals, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · ARS Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ARS Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ARS Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ARS Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”